CN114681392A - Sustained-release oral solid composition - Google Patents
Sustained-release oral solid composition Download PDFInfo
- Publication number
- CN114681392A CN114681392A CN202111628754.8A CN202111628754A CN114681392A CN 114681392 A CN114681392 A CN 114681392A CN 202111628754 A CN202111628754 A CN 202111628754A CN 114681392 A CN114681392 A CN 114681392A
- Authority
- CN
- China
- Prior art keywords
- composition
- acid
- levodopa
- carbidopa
- release component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 46
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 46
- 239000008247 solid mixture Substances 0.000 title claims abstract description 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 72
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 70
- 229960004502 levodopa Drugs 0.000 claims abstract description 68
- 229960004205 carbidopa Drugs 0.000 claims abstract description 32
- 229920000642 polymer Polymers 0.000 claims abstract description 29
- 229920002807 Thiomer Polymers 0.000 claims abstract description 15
- 239000012790 adhesive layer Substances 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 7
- 239000012055 enteric layer Substances 0.000 claims abstract description 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims description 78
- 239000008187 granular material Substances 0.000 claims description 19
- 229920001577 copolymer Polymers 0.000 claims description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 229940081735 acetylcellulose Drugs 0.000 claims description 9
- 229920002301 cellulose acetate Polymers 0.000 claims description 9
- 229960003638 dopamine Drugs 0.000 claims description 9
- 239000010410 layer Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- -1 diethylaminodextran Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 229920001531 copovidone Polymers 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 5
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 5
- 239000008185 minitablet Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000012738 dissolution medium Substances 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 238000011978 dissolution method Methods 0.000 claims description 3
- 238000013265 extended release Methods 0.000 claims description 3
- 210000004051 gastric juice Anatomy 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 235000010338 boric acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims description 2
- 229950005134 polycarbophil Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 229920002714 polyornithine Polymers 0.000 claims description 2
- 108010055896 polyornithine Proteins 0.000 claims description 2
- 230000037452 priming Effects 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005591 trimellitate group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000003361 porogen Substances 0.000 claims 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 23
- 238000000576 coating method Methods 0.000 description 22
- 238000009472 formulation Methods 0.000 description 22
- 239000011248 coating agent Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000008188 pellet Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 238000000889 atomisation Methods 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000006114 decarboxylation reaction Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000005563 spheronization Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010030312 On and off phenomenon Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 235000019424 basic methacrylate copolymer Nutrition 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 239000003954 decarboxylase inhibitor Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004374 Basic methacrylate copolymer Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229910016860 FaSSIF Inorganic materials 0.000 description 1
- 229910005429 FeSSIF Inorganic materials 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000005903 Manganese Poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101150076349 PRRG1 gene Proteins 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 102100028865 Transmembrane gamma-carboxyglutamic acid protein 1 Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- AZDOLIXTFBPILY-UHFFFAOYSA-N butanedioic acid;dihydrate Chemical compound O.O.OC(=O)CCC(O)=O AZDOLIXTFBPILY-UHFFFAOYSA-N 0.000 description 1
- QDMOINLDXCZCEK-JTQLQIEISA-N butyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate Chemical compound CCCCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 QDMOINLDXCZCEK-JTQLQIEISA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229940052036 carbidopa / levodopa Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 description 1
- 229960001820 etilevodopa Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 description 1
- 229960001794 melevodopa Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present disclosure provides a sustained release oral solid composition. Specifically, the present disclosure provides a sustained release oral solid composition, the sustained release component of which comprises: (a) a core comprising levodopa and/or an ester of levodopa or a salt thereof, carbidopa and at least one pharmaceutically acceptable excipient; (b) an adhesive layer surrounding the core comprising a mucoadhesive polymer; (c) an enteric layer surrounding the adhesive layer, comprising an enteric polymer; and (d) a rate controlling component comprising a rate controlling polymer.
Description
Technical Field
The disclosure belongs to the field of medicine, and relates to a sustained-release oral solid composition.
Background
Patients suffering from Parkinson's Disease (PD) often exhibit symptoms of dyskinesia, and abnormally low levels of dopamine (neurotransmitters affecting mobility and control of the skeletal-muscular system) are generally considered to be the major cause of these motor symptoms in PD patients. However, dopamine administration is not effective in treating motor symptoms of parkinson's disease because dopamine does not cross the blood brain barrier. To address this problem, Levodopa (LD), a metabolic precursor of dopamine, is typically administered to PD patients, but has some problems.
Over time, patients treated with LD exhibit symptoms of "hypopharmacodynamic (bearingoff)" in which a single dose of levodopa can no longer last as long as the early phase of levodopa therapy (typically 5-10 years after initiation of levodopa therapy). Such patients can develop motor fluctuations manifested as end-of-dose relapse, peak dyskinesia (akanesia), and akinesia. Advanced forms of motion fluctuation (also commonly referred to as the "on-off" phenomenon) are characterized by unpredictable fluctuations from mobility to immobility. Although the cause of these motor fluctuations is not fully understood, advanced patients typically require a treatment regimen that results in a stable plasma level of LD, such as enteral infusion of LD, due to the presence of the motor fluctuations. However, the intestinal infusion treatment of LD is highly demanding, cumbersome to operate, and traumatic. Oral LD is the most accepted treatment regimen for patients, but it is often difficult to control the plasma concentration levels of oral drugs.
On the other hand, although LD crosses the blood-brain barrier and is rapidly converted to dopamine, LD still has some problems because it is rapidly decarboxylated by tissues other than the brain. When administered orally, levodopa is rapidly decarboxylated to dopamine in the extracerebral tissues, so that only a small fraction of LD can be transported into the central nervous system, while remaining in peripheral tissues causes a series of side effects. Decarboxylase inhibitors, such as Carbidopa (CD), inhibit the decarboxylation of LD, and because their decarboxylase inhibitory activity is localized in the extracerebral tissue, the administration of a decarboxylase inhibitor together with levodopa results in increased transport of levodopa into the brain.
In view of the foregoing, there is a clinical need for LD oral dosage forms with minimal 'peak to valley' fluctuations during daily dosing and with stable blood levels. WO2015054302 discloses an enteric oral formulation comprising LD and CD which, although maintaining relatively stable blood levels over a relatively long period of time, also suffers from a high incidence of side effects (Clin Neuropharmacol, 2019; 42(1): 4-8). it discloses that patients taking IPX-203 formulations have an incidence of side effects of 35.7%.
Disclosure of Invention
To overcome the deficiencies of the prior art, the present disclosure provides a sustained release oral solid composition.
The composition provided by the application can reach the levodopa concentration in blood plasma of more than 50% of the peak plasma concentration (Cmax) (the treatment level of the levodopa) in an extremely short time after a patient takes the composition disclosed by the application, and can maintain the levodopa concentration in blood plasma of more than 50% of the Cmax in a time period of at least 4 hours, preferably at least 4.5 hours, more preferably at least 4.7 hours, so that an infusion-shaped levodopa blood concentration distribution can be realized by taking the medicine orally, the patient is ensured to be in an on-state condition in a longer time, and the time of an off-state and dyskinesia is minimized. Meanwhile, carbidopa in the composition has similar slow release characteristics with levodopa, can continuously inhibit peripheral decarboxylation of levodopa during treatment, and further reduces dopaminergic side effects.
In a first aspect, the present disclosure provides a sustained release oral solid composition comprising a sustained release component comprising: (a) a core comprising levodopa and/or an ester of levodopa or a salt thereof, carbidopa and at least one pharmaceutically acceptable excipient; (b) an adhesive layer surrounding the core, comprising a mucoadhesive polymer; (c) an enteric layer surrounding the adhesive layer, comprising an enteric polymer; and (d) a rate controlling component comprising a rate controlling polymer.
Examples of levodopa include, but are not limited to: levodopa, L-DOPA, L-3, 4-dihydroxyphenylalanine, and (S) -2-amino-3- (3, 4-dihydroxyphenyl) propionic acid.
Examples of carbidopa include, but are not limited to: carbidopa and (S) - α -methyl- α -hydrazino-3, 4-dihydroxyphenylpropionic acid monohydrate.
Examples of esters of levodopa include, but are not limited to: levodopa methyl ester, levodopa ethyl ester, levodopa propyl ester, and levodopa butyl ester. The ester of levodopa may be a salt, including in the case of hydrated salts, in particular, salts of levodopa esters include, but are not limited to: any one of caprylate, myristate, succinate dihydrate, fumarate dihydrate, mesylate, tartrate and hydrochloride.
In some embodiments, the rate controlling component of the sustained release composition: (A) incorporating the core; (B) priming the adhesive layer around the core; (C) doping an adhesion layer; or (D) a combination of any two or three of (A), (B) and (C).
In one embodiment, the rate controlling component surrounds the core and primers the adhesion layer.
In some embodiments, the sustained release component formulation of the present disclosure is formulated as one or more of a powder, a tablet, a mini-tablet, a pill, a bead, or a granule.
In some embodiments, the core of the sustained release component of the present disclosure comprises at least one pharmaceutically acceptable excipient; in some embodiments, the excipient may be selected from one or more of croscarmellose sodium, microcrystalline cellulose, polyvinylpyrrolidone, sodium lauryl sulfate, hydroxypropyl cellulose.
In some embodiments, the adhesion layer of the sustained release component of the present disclosure comprises an anti-tack agent; in some embodiments, the antisticking agent may be selected from one or more of talc, magnesium stearate, glyceryl monostearate.
In some embodiments, the adherent layer of the slow release component of the present disclosure comprises one or more of a plasticizer, an anti-tack agent; in some embodiments, the antisticking agent may be selected from one or more of talc, magnesium stearate, glyceryl monostearate; in some embodiments, the plasticizer may be selected from one or more of triethyl citrate, polyethylene glycol 6000, tributyl citrate, dibutyl sebacate
In yet other embodiments, the compositions of the present disclosure further comprise an immediate release component comprising: levodopa and/or an ester of levodopa or a salt thereof, carbidopa and at least one pharmaceutically acceptable excipient. In some embodiments, the excipient may be selected from one or more of croscarmellose sodium, microcrystalline cellulose, polyvinylpyrrolidone, sodium lauryl sulfate, hydroxypropyl cellulose.
In some embodiments, the immediate release component may be formulated as one or more of a powder, a tablet, a mini-tablet, a pill, a bead, or a granule.
The immediate release component of the present disclosure may further comprise a barrier coating, the coating material may be selected from one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, carnauba wax, methylcellulose, gelatin, cellulose acetate, ethylcellulose, shellac, microcrystalline wax, polyvinyl acetate phthalate, glyceryl behenate, hydroxypropyl methylcellulose phthalate, and hydroxyethyl methylcellulose; in some embodiments, the coating material is selected from one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose; in some embodiments, the coating material is hydroxypropyl cellulose.
In some embodiments, the compositions of the present disclosure further comprise an absorption-promoting component comprising a carboxylic acid selected from one or more of tartaric acid, adipic acid, succinic acid, citric acid, benzoic acid, acetic acid, ascorbic acid, edetic acid, fumaric acid, lactic acid, malic acid, oleic acid, sorbic acid, stearic acid, palmitic acid, and boric acid; tartaric acid is preferred. The absorption enhancing component may be formulated as one or more of a powder, tablet, mini-tablet, pill, bead or granule. The absorption promoting component can improve the end absorption of the levodopa and further prolong the time of the blood concentration staying in the therapeutic window.
Examples of rate controlling polymers suitable for use in the sustained release component of the present disclosure include, but are not limited to: ethyl cellulose, cellulose acetate, Andor mixtures thereof. Preferably, the rate controlling polymer is insoluble in water at neutral pH. In one embodiment, the rate controlling polymer is ethyl cellulose or cellulose acetate; preferably cellulose acetate.
The rate controlling polymer of the present disclosure may comprise 1.0% to 8.0%, preferably 2.0% to 6.0%, more preferably 2.5% to 5%, even more preferably 3.0% to 4.0% by mass of the sustained release component.
To further modulate the release rate, the rate controlling component of the present disclosure may further comprise a pore-forming agent selected from one or more of copovidone, polyethylene glycol, hydroxypropyl methylcellulose, and hydroxyethyl methylcellulose; preferably copovidone.
The pore-foaming agent of the present disclosure may account for 0.5% to 5%, preferably 1% to 3%, more preferably 1.5% to 2% by mass of the sustained-release component.
The mucoadhesive polymer may be composed of a single polymer or a combination of two or more different polymers. Mucoadhesive polymers may have certain characteristics, such as being hydrophilic, hydrophobic, cationic, anionic, and/or biocompatible, for adhering to mucosal surfaces so that the active agent's presence may be extended at the site of absorption to increase bioavailability. In addition, the mucoadhesive polymer may be of natural, synthetic or biological origin. In some embodiments, the size of the polymer may be in the range of 10,000 daltons to 1,000,000 daltons, and more preferably 20,000 daltons to 200,000 daltons.
In some embodiments, the mucoadhesive polymer is selected from one or more of basic methacrylate copolymers, polycarbophil, carbomers, chitosan, diethylaminodextran, diethylaminoethyldextran, polygalactosamine, polylysine, polyornithine, prolamine, polyimine, hyaluronic acid, alginate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and sodium carboxymethyl cellulose.
In some embodiments, the mucoadhesive polymer is an alkaline methacrylate copolymer; preferably aminoalkyl methacrylate copolymers; more preferably butyl methacrylate-dimethylaminoethyl methacrylate-methyl methacrylate (1:2:1) copolymers, e.g.
In some embodiments, the mucoadhesive polymer may comprise from 2.0% to 20.0%, preferably from 5.0% to 15.0%, more preferably from 8.0% to 12.0%, even more preferably from 9.0% to 11.0% by weight of the slow release component.
In some embodiments, the mass ratio of the rate controlling polymer to mucoadhesive polymer in the sustained release component is 1:0.5 to 5, specifically 1:0.5, 1:1, 1:1.5, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9, 1:3.0, 1:3.1, 1:3.2, 1:3.3, 1:3.4, 1:3.5, 1:3.6, 1:3.7, 1:3.8, 1:3.9, 1:4.0, 1:4.1, 1:4.2, 1:4.3, 1:4.4, 1:4.5, 1:4.6, 1:4.7, 1:4.8, 1:4.9, 1: 5.0; preferably 1: 1-4; more preferably 1:2 to 3.
Enteric polymers are designed to prevent drug release from the solid composition in the low pH environment of the stomach, thereby delaying drug release until the dosage form reaches the small intestine. Thus, the sustained release components of the present disclosure have an in vitro release profile with minimal release of the active ingredient at pH 1.0. In the sustained-release component of the present disclosure, the enteric polymer also provides an additional advantage of preventing the sustained-release component from cohering in the low pH environment of the stomach.
In some embodiments, the enteric polymer is selected from one or more of methacrylic acid copolymer, shellac, cellulose acetate phthalate, cellulose acetate trimellitate, poly (vinyl acetate phthalate), hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate.
And in some embodiments, the enteric polymer of the present disclosure is a methacrylic acid copolymer; may be selected from methacrylic acid-ethyl acrylate (1:1) copolymers (e.g.Or) Methacrylic acid-methyl methacrylate (1:1) copolymer (e.g.) And methacrylic acid-methyl methacrylate (1:2) copolymer (e.g.) One or more of; one or both of a methacrylic acid-methyl methacrylate (1:1) copolymer and a methacrylic acid-methyl methacrylate (1:2) copolymer are preferable; more preferably a methacrylic acid-methyl methacrylate (1:1) copolymer.
In some embodiments, the enteric polymer may comprise from 2.0% to 15.0%, preferably from 5.0% to 12.0%, more preferably from 6.0% to 11.0%, even more preferably from 8.0% to 10.0% by weight of the sustained release component.
In some embodiments, the mass ratio of mucoadhesive polymer to enteric polymer in the sustained release component is 1: 0.5-3, specifically 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, 1:1.0, 1:1.05, 1:1.1, 1:1.15, 1:1.2, 1:1.25, 1:1.3, 1:1.35, 1:1.4, 1:1.45, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2.0, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9, 1: 3.0; preferably 1:0.6 to 2; more preferably 1:0.7 to 1.5; even more preferably 1:0.75 to 1.2.
The compositions of the present disclosure may be prepared by granulation methods well known in the pharmaceutical art, including but not limited to: wet granulation, fluidized bed granulation or dry granulation. The sustained release component and/or the immediate release component may additionally contain a lubricant, such as talc. The slow release component and/or the fast release component of the present disclosure may also include a surfactant, such as sodium lauryl sulfate.
The components of the composition of the present disclosure may be used sequentially or after mixing, after formulation, by methods including multiparticulates, tablets, caplets, matrix tablets, and capsules, which may be single or multi-layered. In one embodiment, the composition is encapsulated in a capsule.
In some embodiments, the mass ratio of carbidopa to levodopa in the compositions of the present disclosure is 1: 1-10; preferably 1: 2-5; more preferably 1: 3-4; even more preferably 1:4.
The mass or ratio of carbidopa according to the present disclosure is calculated as the equimolar converted mass of anhydrous carbidopa unless otherwise specified, and similarly, the mass or ratio of levodopa according to the present disclosure is calculated as the equimolar converted mass of levodopa unless otherwise specified.
In some embodiments, the mass ratio of levodopa in the quick release component to the sustained release component is 1: 0.5-5, specifically 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1.0, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1: 5; preferably 1: 1-4; more preferably 1: 2-3; even more preferably 1:3.
In yet other embodiments, the mass ratio of carbidopa in the immediate release component to the sustained release component is 1: 0.1-5, specifically 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1.0, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1: 5; preferably 1:0.2 to 4; more preferably 1:0.5 to 3.
The controlled release components of the present disclosure will exhibit minimal release of levodopa and carbidopa at pH 1.0-2.0 and exhibit a dissolution profile of extended release of levodopa and carbidopa at a pH near neutral, for example at or near pH 7.
The dissolution capacity of the composition or sustained release components of the present disclosure was tested according to the dissolution method specified in the first law of four 0931 of chinese pharmacopoeia 2015 edition, using 900ml of enzyme-free artificial gastric juice at pH 1.6 as dissolution medium at 75 rpm, discarding acid solution at 120min, and then using 900ml of phosphate buffered saline at pH 7.0 as release medium at 75 rpm. In some embodiments, the sustained release component of the compositions of the present disclosure releases up to 10% of levodopa at 120 min; preferably up to 5% levodopa is released; more preferably at most 3% of levodopa is released. In other embodiments, the sustained release component of the compositions of the present disclosure releases up to 10% carbidopa at 120 min; preferably up to 5% carbidopa is released; more preferably up to 3% carbidopa is released.
The levodopa and carbidopa in the sustained release component are continuously dissolved after the pH of the environment is increased, and according to the dissolution test method described above, in one embodiment, the composition of the present disclosure releases at least 90% of the levodopa within 5 to 7 hours. In another embodiment, the composition of the present disclosure releases at least 80% of carbidopa within 4 to 6 hours.
After a patient takes the composition disclosed by the invention, the concentration of levodopa in blood plasma can reach more than 50% of the peak plasma concentration (Cmax) (the therapeutic level of levodopa) in a very short time, and the blood concentration of levodopa is maintained to be more than 50% of the Cmax in at least 4 hours, preferably at least 4.5 hours, more preferably at least 4.7 hours, so that the blood concentration distribution of levodopa in an infusion form can be realized by orally taking a medicine, the patient is ensured to be in an 'on-state' state in a longer time, and the time of 'off-state' and dyskinesia is minimized. Meanwhile, carbidopa in the composition has similar slow release characteristics with levodopa, can continuously inhibit decarboxylation of levodopa during treatment, and further reduces dopa-like side effects in peripheral tissues.
After patients take the composition disclosed by the invention, the incidence rate of the induced adverse reaction is low, and the composition disclosed by the invention has high safety.
In some embodiments, the ratio of carbidopa: the mass ratio of levodopa is any one selected from the group consisting of: (a)17.5 mg: 70 mg; (b)20 mg: 80 mg; (c)22.5 mg: 90 mg; (d)25 mg: 100 mg; (e)30 mg: 120 mg; (f)35 mg: 140 mg; (g)40 mg: 160 mg; (h)45 mg: 180 mg; (i)52.5 mg: 210 mg; (j)60 mg: 240 mg; (k)70 mg: 280mg or (e)87.5 mg: 350 mg; wherein each value can vary by + -10%
In a second aspect, the present disclosure also provides the use of a composition according to the first aspect for the treatment of a disorder associated with reduced levels of dopamine. Diseases associated with reduced dopamine levels include neurological or movement disorders such as restless leg syndrome, Alzheimer's disease, dystonia, schizophrenia, Parkinson's disease, Huntington's disease, attention deficit/hyperactivity disorder (ADHD), snow-du syndrome (she-Drager syndrome), and conditions caused by brain injury including carbon monoxide or manganese poisoning.
In some embodiments, the composition of the first aspect is used to treat parkinson's disease or parkinsonism.
Moreover, the numerical ranges and parameters setting forth the disclosure are approximate, and numerical values related to particular embodiments are presented herein as precisely as possible. Any numerical value, however, inherently contains certain standard deviations found in their respective testing measurements. Accordingly, unless expressly stated otherwise, it is understood that all ranges, amounts, values and percentages used in this disclosure are by weight modified by "about". As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range.
Detailed Description
1. Experimental reagent
2. Laboratory apparatus
Serial number | Name of instrument | Source |
1 | TMG1/6 wet granulator | Glatt |
2 | IPS-25 extrusion rounding machine | GEA |
3 | DPL-II fluidized bed | Chongqing Seiko |
4 | GPCG1.1 fluidized bed | Glatt |
3. Examples of the embodiments
3.1 example 1 preparation of immediate Release granules
The formulation of the immediate release granules is shown in table 1.
TABLE 1 quick-release granule formulation composition
The preparation process comprises the following steps:
1) preparing a soft material: adding the weighed and prepared levodopa, carbidopa (monohydrate), microcrystalline cellulose PH101, croscarmellose sodium and povidone K30 into a granulator, setting the stirring speed to be 200rpm and the cutter speed to be 1500rpm, and carrying out dry mixing. While continuing the mixing, purified water was added as a wetting agent and wet shearing was carried out at a stirring speed of 200rpm and a cutter speed of 2000 rpm.
2) Extruding and rounding to prepare the pellets: extruding and rounding by using an extruding and rounding machine, wherein the screen mesh type is as follows: 0.8 × 0.7, impeller speed 35rpm, stirring speed: 25rpm, spheronization speed: 500 rpm.
3) And (3) drying the pellets: drying the vegetarian ball by using a fluidized bed, setting the air inlet temperature at 70 ℃ and the air inlet frequency at 25Hz until the water content is less than or equal to 2.0 percent.
4) Screening: and (4) screening the dried pellets by using 20-mesh and 30-mesh screens, and taking the pellets between 20 meshes and 30 meshes.
5) Coating: water at 70 ℃ was added to the vessel and stirring was started, while stirring, hypromellose was slowly added to the vortex of solvent and mixing was continued until the copolymer was completely dissolved. After calibration of the spray rate, glaster GPCG1.1 equipped with a worster insert was used for coating at an inlet temperature of 45 ℃, an atomization gas pressure of 1.5bar and a worster septum height of 20 mm. After spraying the target amount of coating solution, it was dried at an inlet temperature of 50 ℃.
3.2 example 2 preparation of sustained Release granules
The formulation of the sustained release granules is shown in table 2.
TABLE 2 sustained Release granule formulation
The preparation process comprises the following steps:
1) soft mass preparation, 2) pellet preparation by extrusion spheronization, 3) pellet drying and 4) sieving the same as in example 1.
4) Coating a film control layer: cellulose acetate and copovidone (Kollidon VA64) were completely dissolved in a mixed solution of acetone and isopropanol solution. After calibration of the spray rate, glaster GPCG1.1 equipped with a worster insert was used for coating at an inlet temperature of 30 ℃, an atomization gas pressure of 1.5bar and a worster septum height of 20 mm. After spraying the target amount of coating solution, it was dried at an inlet temperature of 30 ℃.
5) Yutex E100 coating: dissolving Eiteqi E100 in ethanol under stirring, adding pulvis Talci to form suspension, and stirring continuously during coating process. After calibration of the spray rate, glaster GPCG1.1 equipped with a worster insert was used for coating at an inlet temperature of 30 ℃, an atomization gas pressure of 1.5bar and a worster septum height of 20 mm. After spraying the target amount of coating solution, the coated beads were dried at an air inlet temperature of 30 ℃.
6) Enteric coating: completely dissolving Eiteqi L100 in ethanol under stirring, adding triethyl citrate and pulvis Talci to form suspension, and stirring continuously during coating process. After calibration of the spray rate, glaster GPCG1.1 equipped with a worster insert was used for coating at an inlet temperature of 30 ℃, an atomization gas pressure of 1.5bar and a worster septum height of 20 mm. After spraying the target amount of coating solution, it was dried at an air inlet temperature of 30 ℃.
3.3 example 3 preparation of absorption promoting particles
The formulation of the absorption enhancing particles is shown in table 3.
TABLE 3 prescription composition of absorption-promoting granules
The preparation process comprises the following steps:
1) soft mass preparation, 2) extrusion spheronization for pellet preparation, 3) pellet drying and 4) sieving the pellets as in example 1, with the only difference that the spheronization speed is 700 rpm.
5) Coating of the slow release layer: separately, a prescribed amount of HPMC (E5) was dissolved in hot water, a prescribed amount of ethylcellulose was dissolved in absolute ethanol, and after complete dissolution, the two solutions were mixed together and stirred. Glaster GPCG1.1 equipped with a worsted insert was used for coating at an inlet air temperature of 30 ℃, an atomisation air pressure of 1.5bar and a worsted septum height of 20 mm. After spraying the target amount of coating solution, it was dried at an inlet temperature of 30 ℃.
6) Enteric coating: adding the Eudragit L100 and S100 into 95% ethanol, adding triethyl citrate and talcum powder after completely dissolving to form a suspension, and continuing stirring. After calibration of the spray rate, glaster GPCG1.1 equipped with a worster insert was used for coating at an inlet temperature of 30 ℃, an atomization gas pressure of 1.5bar and a worster septum height of 20 mm. After spraying the target amount of coating solution, it was dried at an inlet temperature of 30 ℃.
3.4 example 4 preparation of composition capsules
The capsules were obtained by filling according to the proportions in table 4.
TABLE 4 fill-in amount of capsules (specification: carbidopa/levodopa ═ 43.75 mg: 175mg)
Code for preparation | Immediate release granules/mg | Sustained release granule/mg | Absorption promoting granule/mg |
T1 | Prescription A73.62 | Prescription I298.54 | / |
T2 | Prescription A73.62 | Prescription II 299.80 | / |
T3 | Prescription A73.62 | Prescription I298.54 | Prescription a 175 |
T4 | Prescription A73.62 | Prescription I298.54 | Prescription b 267.19 |
T5 | Prescription A73.62 | Prescription III 269.32 | / |
T6 | Prescription B93.96 | Prescription IV 271.09 | / |
3.5 preparation of T7 capsules
Immediate release and sustained release granules were prepared in a similar manner to examples 1 and 2 in accordance with the proportions of formulation C shown in table 5 and formulation V shown in table 6, and filled in a capsule according to the proportion of formulation C70.94 mg/formulation V252.89 mg (specification: carbidopa/levodopa-43.75 mg: 175mg) to obtain T7 capsules.
TABLE 5 prescription composition of immediate release granules of T7
TABLE 6 prescription composition of sustained-release granules of T7
Biological test evaluation
The present invention is further described and illustrated below in conjunction with specific examples thereof, which are not intended to limit the scope of the present invention.
1. Experimental reagent
Serial number | Reagent | Source |
1 | Hydrochloric acid | SINOPHARM CHEMICAL REAGENT Co.,Ltd. |
2 | Sodium hydroxide | Shanghai Lingfeng Chemicals Co., Ltd |
3 | Sodium dihydrogen phosphate dihydrate | SINOPHARM CHEMICAL REAGENT Co.,Ltd. |
4 | Sodium chloride | SINOPHARM CHEMICAL REAGENT Co.,Ltd. |
5 | FaSSIF/FeSSIF/FaSSGF | Biorelevant.com Ltd |
2. Laboratory apparatus
Serial number | Instrument for measuring the position of a moving object | Source |
1 | AT-7smart dissolution instrument | SOTAX |
2 | 708-DS dissolution instrument | Agilent |
3. Test example
3.1 in vitro dissolution test
According to the dissolution determination method (first method of 0931 in four parts of the Chinese pharmacopoeia 2015 edition), 900ml of enzyme-free artificial gastric juice with pH of 1.6 is used as dissolution medium, the rotation speed is 75 r/min, the acid solution is discarded at 120min, 900ml of phosphate buffer with pH of 7.0 is used as release medium, and the rotation speed is 75 r/min. The cumulative release of each component of the capsules of formulations T1 to T3 and T5 to T6 is shown in table 7; the cumulative release of each ingredient from the capsules of formulations T4 and T7 is shown in table 8.
TABLE 7 cumulative release (%) -of the capsules T1 to T3 and T5 to T6
TABLE 8 cumulative Release (%) -of T4 and T7 capsules
The cumulative release profiles of sustained release granule formulations I and II were determined according to the above dissolution test method, and the results are shown in Table 9.
TABLE 9 cumulative Release (%)
The basic methacrylate copolymer contained in the adhesive layer and the methacrylic acid copolymer contained in the enteric layer contain amino groups, so that ionic interaction can occur between the two polymers, and the viscosity, swelling behavior and the like of the polymers can change along with the difference of the types and the proportions of the polymers, which is proved by related documents (J Control Release, 2005; 103: 191-198). The sustained release component of the present disclosure further comprises a rate controlling component, which further comprises a polymer containing carboxyl groups, which forms a more complex carboxyl-amino-carboxyl ionic interaction system with the adhesion layer and the enteric layer, and in addition, the active component also comprises acidic and basic groups, which makes the swelling and release characteristics of the sustained release component as a whole more difficult to predict.
The composition disclosed by the invention has more excellent carbidopa sustained release data compared with a control on the basis of stable and long-acting levodopa release characteristics, which suggests that the carbidopa in the prescription disclosed by the invention can continuously inhibit the decarboxylation of the levodopa for a relatively long time, and thus the side effects of peripheral tissues caused by the decarboxylation of the levodopa are greatly relieved.
3.2 in vivo pharmacokinetic testing
3.2.1 run 1
The study adopts a single-center, random, open, four-cycle cross test design, and a 3-day cleaning period is used in the cycle. Subject: 12 healthy subjects were planned for selection, with no restriction.
The test method comprises the following steps: the study is divided into 6 stages of screening period, 1 st period, 2 nd period, 3 rd period, 4 th period and post-test physical examination. And (3) screening period: and (3) the subjects are fully informed 7 days before the administration to 1 day before the administration, and are screened and checked after signing an informed consent book, and are subjected to a group test after the subjects are qualified. Cycle 1: subjects were admitted to phase i ward 1 day prior to dosing and fasted for at least 10 hours prior to dosing. Drugs T1, T2 or IPX-066 were tested orally on a single fasting basis on a random schedule on the morning of the day of administration. Drinking water is prohibited before and 1 hour after taking medicine, and fasting is performed within 4 hours after taking medicine. About 4mL of elbow venous blood was collected at 0h before administration (within 1h before administration) and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0, 8.0, 10.0, 12.0, 14.0h after administration; vital signs were measured at enrollment, within 1h prior to dosing and 2 (+ -1) h, 4 (+ -1) h, 8 (+ -1) h, 14 (+ -1) h post-dosing, and adverse events were recorded during the course of the experiment. The first cycle procedure was repeated for the second, third and fourth cycles, with a 3-day wash period between cycles.
Administration dose: the test preparation T1, T2, T3350 mg or the reference preparation IPX-066 (trade name) were administered according to a random schedule every cycle)245mg。
The results of the pharmacokinetic experiments are shown in table 10.
TABLE 10 sample in vivo pharmacokinetic test data
As can be seen from the test results, T1, T2 and T3 all achieved longer than the reference formulation IPX-066>The blood concentration fluctuation degree of the 50% Cmax time and T1 and T2 is lower than that of the reference preparation; cmax and AUC of T1, T2, T3 and reference preparation converted to equal dosage0-tData are comparable, Cmax and AUC for T1 formulations0-tHas significantly lower inter-individual variation (RSD%) than that of ginsengThe preparation is prepared.
3.2.2 run 2
The study adopts a single-center, random, open, four-cycle cross test design, and a 3-day cleaning period is used in the cycle. Subject: 16 healthy subjects were scheduled for inclusion, with no restriction.
The test method comprises the following steps: the study is divided into 6 stages of screening period, 1 st period, 2 nd period, 3 rd period, 4 th period and post-test physical examination. And (3) screening period: and (3) the subjects are fully informed 7 days before the administration to 1 day before the administration, and are screened and checked after signing an informed consent book, and are subjected to a group test after the subjects are qualified. Cycle 1: subjects were admitted to the hospital 1 day prior to dosing and fasted for at least 10 hours prior to dosing. Test drugs T5, T6, control or reference formulation IPX-066 were administered orally on a single fasting basis on a random schedule on the morning of the day of administration. Drinking water is forbidden before and 1 hour after the medicine is taken, and fasting is not carried out within 4 hours after the medicine is taken. About 4mL of elbow venous blood was collected at 0h before administration (within 1h before administration) and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 7.0, 8.0, 10.0, 12.0, 14.0h after administration; vital signs were measured at enrollment, within 1h prior to dosing, and 2 (+ -1) h, 4 (+ -1) h, 8 (+ -1) h, 14 (+ -1) h post-dose, and adverse events were recorded during the course of the experiment. The first cycle procedure was repeated for the second, third and fourth cycles, with a 3-day wash period between cycles. Administration dose: the test preparation T5, T6, T7350 mg or the reference preparation IPX-066 (trade name) were administered according to a random schedule every cycle)390 mg. The results of the pharmacokinetic experiments are shown in table 11.
TABLE 11 sample in vivo pharmacokinetic test data
The incidence of adverse reactions is shown in table 12.
TABLE 12 incidence of adverse reactions
Product name | Incidence of treatment-induced adverse reactions | Remarks for note |
IPX-203 (literature) | 35.7% | A total of 28 patients with advanced PD participating in the study |
T5 | 18.75% | Participating in the study a total of 16 healthy subjects |
T6 | 12.5% | Participating in the study a total of 16 healthy subjects |
T7 | 31.25% | Participating in the study a total of 16 healthy subjects |
Reference formulation IPX-066 | 18.75% | A total of 16 healthy subjects participated in the study |
Note: adverse reactions concerned in this study were fatigue, dizziness, lacrimation, fever, muscle soreness, headache, dyspepsia and pregnancy;
it can be seen from the test results that T5, T6 and T7 all achieved > 50% Cmax maintenance times longer than the reference formulation IPX-066, the blood levels of T5, T6 and T7 fluctuated less than the reference formulation and the inter-individual variability (RSD%) was significantly lower than the reference formulation. Meanwhile, the incidence of adverse reactions induced by the treatment of T5, T6 and T7 is lower than that of IPX-203.
Claims (28)
1. An extended release oral solid composition comprising an extended release component comprising: (a) a core comprising levodopa and/or an ester of levodopa or a salt thereof, carbidopa and at least one pharmaceutically acceptable excipient; (b) an adhesive layer surrounding the core comprising a mucoadhesive polymer; (c) an enteric layer surrounding the adhesive layer, comprising an enteric polymer; and (d) a rate controlling component comprising a rate controlling polymer.
2. The composition of claim 1, wherein the rate controlling component: (A) incorporating the core; (B) priming the adhesive layer around the core; (C) doping an adhesion layer; or (D) a combination of any two or three of (A), (B) and (C).
3. The composition of claim 1 or 2, wherein the rate controlling component surrounds the core and primers the adherent layer.
4. The composition according to any one of claims 1 to 3, wherein the sustained release component is formulated as one or more of a powder, a tablet, a mini-tablet, a pill, a bead or a granule.
5. The composition of any one of claims 1-4, further comprising an immediate release component comprising: levodopa and/or an ester of levodopa or a salt thereof, carbidopa and at least one pharmaceutically acceptable excipient.
6. The composition of claim 5, wherein the immediate release component comprises excipients selected from one or more of croscarmellose sodium, microcrystalline cellulose, polyvinylpyrrolidone, sodium lauryl sulfate, and hydroxypropyl cellulose.
7. The composition of claim 6, wherein the immediate release component is formulated as one or more of a powder, a tablet, a mini-tablet, a pill, a bead, or a granule.
8. The compound according to any one of claims 1-7, further comprising an absorption-promoting component comprising a carboxylic acid selected from one or more of tartaric acid, adipic acid, succinic acid, citric acid, benzoic acid, acetic acid, ascorbic acid, edetic acid, fumaric acid, lactic acid, malic acid, oleic acid, sorbic acid, stearic acid, palmitic acid, and boric acid; tartaric acid is preferred.
9. The composition of any of claims 1-8, wherein the rate controlling polymer is ethyl cellulose or cellulose acetate; preferably cellulose acetate.
10. The composition of any one of claims 1-9, the rate controlling component further comprising a porogen selected from one or more of copovidone, polyethylene glycol, hydroxypropyl methylcellulose, and hydroxyethyl methylcellulose; preferably copovidone.
11. The composition according to any one of claims 1 to 10, wherein the mucoadhesive polymer is selected from one or more of the group consisting of alkaline methacrylate copolymers, polycarbophil, carbomer, chitosan, diethylaminodextran, diethylaminoethyldextran, polygalactosamine, polylysine, polyornithine, prolamine, polyimine, hyaluronic acid, alginate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and sodium carboxymethylcellulose.
12. The composition of any of claims 1-11, wherein said mucoadhesive polymer is an alkaline methacrylate copolymer; preferably aminoalkyl methacrylate copolymers; more preferred is a butyl methacrylate-dimethylaminoethyl methacrylate-methyl methacrylate (1:2:1) copolymer.
13. The composition of any of claims 1-12, wherein the mass ratio of the rate-controlling polymer to mucoadhesive polymer in the sustained-release component is 1:0.5 to 5; preferably 1: 1-4; more preferably 1:2 to 3.
14. The composition according to any one of claims 1 to 13, wherein the enteric polymer is selected from one or more of methacrylic acid copolymer, shellac, cellulose acetate phthalate, cellulose acetate trimellitate, poly (vinyl acetate phthalate), hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate.
15. The composition of any of claims 1-14, wherein the enteric polymer is a methacrylic acid copolymer; preferably one or more selected from methacrylic acid-ethyl acrylate (1:1) copolymer, methacrylic acid-methyl methacrylate (1:1) copolymer and methacrylic acid-methyl methacrylate (1:2) copolymer; more preferably one or both of a methacrylic acid-methyl methacrylate (1:1) copolymer and a methacrylic acid-methyl methacrylate (1:2) copolymer; even more preferably a methacrylic acid-methyl methacrylate (1:1) copolymer.
16. The composition of any of claims 1-15, wherein the weight ratio of mucoadhesive polymer to enteric polymer in the sustained release component is 1:0.5 to 3; preferably 1:0.6 to 2; more preferably 1:0.7 to 1.5; even more preferably 1:0.75 to 1.2.
17. The composition of any one of claims 1-16, wherein the composition is encapsulated in a capsule.
18. The composition according to any one of claims 1 to 17, wherein the mass ratio of carbidopa to levodopa is 1:1 to 10; preferably 1: 2-5; more preferably 1: 3-4; even more preferably 1:4.
19. The composition according to any one of claims 1 to 18, wherein the mass ratio of the levodopa in the quick release component to the sustained release component is 1: 0.5-5; preferably 1: 1-4; more preferably 1: 2-3; even more preferably 1:3.
20. The composition of any of claims 1-19, wherein the mass ratio of carbidopa in the immediate release component to carbidopa in the sustained release component is 1:0.1 to 5; preferably 1:0.2 to 4; more preferably 1:0.5 to 3.
21. The composition according to any one of claims 1-20, wherein 900ml of the enzyme-free artificial gastric juice having a pH of 1.6 is used as dissolution medium at 75 rpm according to the dissolution method specified in the first law of the fourth 0931 of the pharmacopoeia 2015 edition of china, the acid solution is discarded at 120min, and 900ml of phosphate buffer having a pH of 7.0 is used as release medium at 75 rpm; the sustained release component releases up to 10% of levodopa at 120 min; preferably up to 5% levodopa is released; more preferably at most 3% of levodopa is released.
22. The composition of claim 21, wherein said sustained release component releases up to 10% carbidopa at 120 min; preferably up to 5% carbidopa is released; more preferably up to 3% of carbidopa is released.
23. The composition according to any of claims 1-22, wherein 900ml of enzyme-free artificial gastric fluid at pH 1.6 is used as dissolution medium at 75 rpm, the acid solution is discarded at 120min, followed by 900ml of phosphate buffered saline at pH 7.0 as release medium at 75 rpm, according to the dissolution method specified in the first law of the four 0931 parts of the chinese pharmacopoeia 2015 edition; the composition releases at least 90% of levodopa within 5-7 hours.
24. The composition of claim 23, wherein said composition releases at least 80% carbidopa within 4 to 6 hours.
25. The composition according to any of claims 1-24, wherein the in vivo levodopa plasma concentration is maintained at or above 50% Cmax for at least 4 hours, preferably at least 4.5 hours, more preferably 4.7 hours.
26. The composition of any one of claims 1-25, wherein the ratio of carbidopa: the mass ratio of levodopa is any one selected from the group consisting of:
(a)17.5 mg: 70 mg; (b)20 mg: 80 mg; (c)22.5 mg: 90 mg; (d)25 mg: 100 mg; (e)30 mg: 120 mg; (f)35 mg: 140 mg; (g)40 mg: 160 mg; (h)45 mg: 180 mg; (i)52.5 mg: 210 mg; (j)60 mg: 240 mg; (k)70 mg: 280mg or (e)87.5 mg: 350 mg; wherein each value can vary by ± 10%.
27. Use of a composition according to any one of claims 1 to 26 in the manufacture of a medicament for the treatment of a condition associated with reduced levels of dopamine.
28. Use of a composition according to any one of claims 1 to 26 in the manufacture of a medicament for the treatment of parkinson's disease or parkinsonism.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011590086 | 2020-12-29 | ||
CN202011590086X | 2020-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114681392A true CN114681392A (en) | 2022-07-01 |
Family
ID=82136913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111628754.8A Pending CN114681392A (en) | 2020-12-29 | 2021-12-28 | Sustained-release oral solid composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114681392A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116159037A (en) * | 2023-04-25 | 2023-05-26 | 四川省川龙动科药业有限公司 | Targeted pellet composition for preventing and treating piglet colitis and preparation method thereof |
WO2024078607A1 (en) * | 2022-10-14 | 2024-04-18 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method therefor |
-
2021
- 2021-12-28 CN CN202111628754.8A patent/CN114681392A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024078607A1 (en) * | 2022-10-14 | 2024-04-18 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method therefor |
CN116159037A (en) * | 2023-04-25 | 2023-05-26 | 四川省川龙动科药业有限公司 | Targeted pellet composition for preventing and treating piglet colitis and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104958282B (en) | Tapentadol hydrochloride composition | |
ES2606463T3 (en) | Combination of levodopa / carbidopa immediate release and controlled release dosage forms | |
AU2019268052A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
US10449159B2 (en) | Methods and compositions particularly for treatment of attention deficit disorder | |
AU2013344281B2 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
EP2623099A1 (en) | Composition and method for treating neurological disease | |
JP2017014295A (en) | Controlled release formulations of levodopa and uses thereof | |
TWI483748B (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
JP2004518676A (en) | Sustained release pharmaceutical dosage form with minimized pH dependent dissolution profile | |
JP2008528494A (en) | Pharmaceutical formulations and methods of use | |
JP2023513249A (en) | Omecamtib mecarbyl formulation | |
CN114681392A (en) | Sustained-release oral solid composition | |
MXPA06002023A (en) | Novel formulation. | |
CA2866276A1 (en) | Controlled-release solid dosage forms of mesalamine | |
KR102276896B1 (en) | Fixed dose combination therapy of parkinson's disease | |
CA3016852A1 (en) | A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd) | |
JPH09508381A (en) | Controlled release metronidazole composition and methods of making and using the same | |
AU2018322756B2 (en) | Composition comprising suplatast tosilate | |
RU2771522C9 (en) | Parkinson’s disease therapy using combination with fixed dosages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |